




FIG. 1




FIG. 2A







FIG. 2B






FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 22C

COMBINATION OF 350.B AND ANTI-PD-1 ANTIBODY TREATMENT SHOWS GREATER ANTI-TUMOR ACTIVITY THAN EITHER SINGLE AGENT IN A MODEL OF CT-26 COLON CARCINOMA




FIG. 23

DETECTION OF BIOTINYLATED 373.A ON UNLABELED 373.A
PRETREATED BLOOD SAMPLES




FIG. 24A




FIG. 24B

373.A RESTORES PROLIFERATION IN CD4+ T CELLS
(SUPPRESSED BY AMP DURING TCR-MEDIATED ACTIVATION)




FIG. 25A

373.A RESTORES PROLIFERATION IN CD8+ T CELLS
(SUPPRESSED BY AMP DURING TCR-MEDIATED ACTIVATION)




FIG. 25B

MCPRAARAPATLLAALGAVLWPAAGAWELTILHTNDVHSRIEQTS~~EDSSKCVNASRC~~
MGGVARLFTTKVQOQIRRAEPNVLLLDAGDOYQGTINFTVYKGA~~EVAFHFMNALR~~YDA
MALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVG
IVGYTSKETPFELSNPGTNLVFEDEITALQPEVDKIKTLNVNKIIAIGHSGFEMDKLIAQKV
RGVDVVGGHSNTFLYTGNPSPSKEVPAGKYPFIVTSDDGKRVVQAYAFGKYLGYLKI
EFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSC
RFRECNMGNLICDAMINNNLRHADETFWNHVS~~MCILNGGGIRSPIDER~~NNGTITWE
NLA~~AVL~~PFEGGTFDLVQLKGSTLKKA~~FEHSVHRYGQSTGEFLQVGGIHVVYDLSRK~~PGD
RVVKLDVLC~~TKCRVPSYDPLKMDEVYKVILENFLANGDGFQMIKDEILRHDSGDQDI~~
NVVSTYISKMKVIYPAVEGRIKHHHHHH (SEQ ID NO: 332)

FIG. 26A

MCPRARAPATLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSSESSKCVNASRC
MGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFVYKGAEVAHFMAALRYDA
MALGNHEFDNGVEGLIEPLLKEA**KFP**ILSANIKAKGPLASQISGLYLPYKYVLPVGVDEW
GIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLTNLNVNKIIALGHSGFEMDKLIAQK
VRGVDVVVGHSNTELYTGNPPSKEVPAGKYFFIVTSDDGKVPVQAYAFGKYLGYL
KIEFDERGNVISSHGNIILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQS
CRFRECNMGNLICDAMINNNLRHADETFWNHVSMCIINGGGIRSPIDERNNGTITW
ENLAAVL PFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPG
DRVVKLDVLCCKRVPSYDPLKMDEVYKVILPNFLANGDGFQMIKDELLRHDSGDQ
DINVVSTYISKMKVIYPAVEGRICKHHHHH (SEQ ID NO: 332)

FIG. 26B

QVQLQESGPGLVKPSSETLSLTCTVSGGSIERYYMSWIRQPPGKGLEWIGYIYGRGS
TNYNPSLKSRVTISVDTSKNQFSLKLSVTAADTAVYCARESQESPYNWFDPW
GQGTILVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDHKPSNTKVKDKRVESKYG
P (SEQ ID NO: 331)

FIG. 26C

QVQLQESGPGLVKPSSETLSLTCTVSGGSIERYYMSWIRQPPGKGLEWIGYIYGRGS
TNYNPSLKSRVTISVDTSKNQFSLKLSVTAADTAVYCARESQESPYNWFDPW
GQGTILVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDHKPSNTKVKDKRVESKYG
P (SEQ ID NO: 331)

FIG. 26D

MCPRAARAPATILLALGAVLNPAAGAWELTILHTNDVHSRLEQTS~~EDSSKCVNASRC~~
MGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTWFTVYKGA~~EV~~AHF~~MNAL~~RYDA
MALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVG
IVGYTSKETPFILSNPGTNLVFEDEITALQPEVDKLTFTNVNKIIALGHSGFEMDKLIAQKV
RGVDVVGHSNTFLYTGNPSPKEVPAGKYPFIVTSDDGKVPVQYAFGKYLGYLKI
EFDERGNVISSHGNPILNSSIPEDPSIKADINKWRIKLDNYSTQELGKTTVYLDGSSQSC
RFRECNMGNLICDAMINNNLRHADETFWNHVS~~MCIL~~NGGGIRSPIDER~~NNGT~~ITWE
NLAAVL~~PFGG~~FDLVQLKGSTLKKAFESHVHRYGQSTGEFLQVGGIHVVYDLSRKPGD
RVVKLDVLC~~TKR~~VPSPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDI
NVVSTYISKMKVITYPAVEGR~~IKHHHHH~~ (SEQ ID NO: 332)

FIG. 26E

MCPRAARAPATLLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSKCVNASRC
MGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGA~~EV~~AHF~~M~~NALRYDA
MALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVG
IVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTTNNVNKIIALGHSGFEMDKLIAQKV
RGVDVVGGHSNTFLYTGNPSPSKEVPAGKYPFIVTSDDGRKVPVQAYAFGKYLGYLKI
EFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIIVLDGSSQSC
RFRECNMGNLICDAMINNNLRHADETFWNHVSVCILNGGGIRSPIDERNNGTITWE
NLA~~AV~~LPFGGTFDLVQLKGSTLKKA~~FE~~HSVHRYGQSTGEFLQVGGIHVVYDLSRKPGD
RVVKLDVLC~~T~~KCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDI
NVVSTYISKMKVIYPAVEGRIKHHHHH (SEQ ID NO: 332)

FIG. 26F

DIQMTQSPSSVSASVGDRVITITCRASQGISS~~W~~LAWYQQKPGKAPKLLIYAASSLQSG
VPSRFGSGSGTDFTLTISSLQPEDFAITYCQQGNSEFPRTEGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSST
YSLSSITLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 23)

FIG. 26G

DIQMTQSPSSVSASVGDRVITITCRASQGI~~SS~~~~W~~LAWYQQKPGKAPKLLIYAASSLQSG
VPSRFGSGSGTDFTLTISSLQPEDFAITYCQQGNSEFPRTEGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSST
YSLSSITLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 23)

FIG. 26H

30s LABELING CD73 NORMALIZED RATIO RELATIVE TO CD73

374 377 379 373 350





FIG. 27A

30s LABELING CD73 NORMALIZED RATIO RELATIVE TO CD73

374 377 379 373 350



LYSINE RESIDUE

FIG. 27B

300s LABELING CD73 NORMALIZED RATIO RELATIVE TO CD73

374 377 379 373 350





FIG. 28A

300s LABELING CD73 NORMALIZED RATIO RELATIVE TO CD73

374 377 379 373 350



LYSINE RESIDUE

FIG. 28B